Business
AI Diagnostics: The End of the High-Cost Imaging Era
VANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) --   Equity-Insider.com News...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"AI Diagnostics: The End of the High-Cost Imaging EraIssued on behalf of VentriPoint Diagnostics Ltd.\nVANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) --  Equity-Insider.com News Commentary – The AI medical imaging market is entering a phase of explosive 25.8% annual growth through 2034[1]. This systemic re-rating is driven by healthcare’s structural pivot from bulky, expensive hardware to agile, software-defined intelligence. As diagnostics move out of specialized labs and into decentralized, point-of-care environments[2], institutions are rotating capital into a first-mover cohort capable of delivering MRI-grade accuracy on the fly. This secular transition is positioning VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Heartflow (NASDAQ: HTFL), AtriCure (NASDAQ: ATRC), Edwards Lifesciences (NYSE: EW), and CeriBell (NASDAQ: CBLL) as the primary engines for democratized diagnostic intelligence in 2026.The real value catalyst arrives in July 2026 with the launch of CMS’s new ACCESS Model, which introduces outcome-aligned payments for technology-supported care[3]. This creates a direct, lucrative reimbursement pathway for scalable AI platforms that can prove they actually save lives and dollars. Value-based care is reaching a digital tipping point in 2026[4], where connected platforms are no longer a \"nice-to-have\" but a survival requirement for healthcare providers. In this new landscape, software-defined imaging platforms are the load-bearing walls of the industry, allowing clinics to aggregate clinical data at scale while delivering a measurable return on investment. Ventripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is building subscription models that promise measurable returns for hospitals. The company transforms standard 2D ultrasound images into 3D volumetric models with MRI-level accuracy for heart assessments. Strong investor demand just doubled their private placement from $500,000 to $1 million. The proceeds will fund critical commercialization activities, manufacturing scale-up, continued regulatory submissions, and operational requirements. The real shift happening here is about proving economic value rather than just clinical capability. Ventripoint recently engaged Summit Sciences, a specialized consulting firm, to develop advanced ROI models that show healthcare providers...